All In Biotech

Drug Trial Radar · NCT05334108

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study to Evaluate the Effects of Repeat Titrated Doses of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Apr 26, 2022

Primary completion

Aug 1, 2022

Study completion Aug 26, 2022

Sponsor

Lead sponsor
Emalex Biosciences Inc.Industry
Sponsor type
Industry
Collaborators
ICON plc; Nuventra, Inc.
First posted
Apr 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.

Conditions

  • Drug Interaction

Interventions

  • EcopipamDrug

    ecopipam HCl \~2mg/kg/day

  • Cohort 1 Probe Substrate CocktailCombination product

    dextromethorphan, caffeine, omeprazole, and midazolam

  • Cohort 2 Probe SubstrateDrug

    bupropion

  • Cohort 3 Probe Substrate CocktailCombination product

    dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
  2. Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
  3. Cmax of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
  4. Cmax oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
  5. Cmax of dabigatran in the presence of ecopipamTime frame: Up to Day 22
  6. Cmax of dabigatran in the absence of ecopipamTime frame: Up to Day 22
  7. Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 22
  8. Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 22
  9. Cmax of rosuvastatin in the presence of ecopipamTime frame: Up to Day 22
  10. Cmax of rosuvastatin in the absence of ecopipamTime frame: Up to Day 22
  11. Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 22
  12. Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 22
  13. AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
  14. AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
  15. AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
  16. AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
  17. AUCinf of dabigatran in the presence of ecopipamTime frame: Up to Day 22
  18. AUCinf of dabigatran in the absence of ecopipamTime frame: Up to Day 22
  19. AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 22
  20. AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 22
  21. AUCinf of rosuvastatin in the presence of ecopipamTime frame: Up to Day 22
  22. AUCinf of rosuvastatin in the absence of ecopipamTime frame: Up to Day 22
  23. AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 22
  24. AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 22
  25. AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
  26. AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
  27. AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
  28. AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
  29. AUClast of dabigatran in the presence of ecopipamTime frame: Up to Day 22
  30. AUClast of dabigatran in the absence of ecopipamTime frame: Up to Day 22
  31. AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 22
  32. AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 22
  33. AUClast of rosuvastatin in the presence of ecopipamTime frame: Up to Day 22
  34. AUClast of rosuvastatin in the absence of ecopipamTime frame: Up to Day 22
  35. AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 22
  36. AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 22
  37. AUC0-24 of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 22
  38. AUC0-24 of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 22
  39. AUC0-24 of dabigatran in the presence of ecopipamTime frame: Up to Day 22
  40. AUC0-24 of dabigatran in the absence of ecopipamTime frame: Up to Day 22
  41. AUC0-24 of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 22
  42. AUC0-24 of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 22
  43. AUC0-24 of rosuvastatin in the presence of ecopipamTime frame: Up to Day 22
  44. AUC0-24 of rosuvastatin in the absence of ecopipamTime frame: Up to Day 22
  45. AUC0-24 of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 22
  46. AUC0-24 of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Phase Services

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.